Semaglutide
From Proteopedia
(Difference between revisions)
| Line 5: | Line 5: | ||
Semaglutide was discovered in an effort to increase the lifetime of a once-a-day medication called Liraglutide. It is derived from the GLP-1 hormone, contains two amino acid sequence changes and a covalently attached lipid. | Semaglutide was discovered in an effort to increase the lifetime of a once-a-day medication called Liraglutide. It is derived from the GLP-1 hormone, contains two amino acid sequence changes and a covalently attached lipid. | ||
| - | ==Structure== | + | ==Structure and Receptor Binding== |
<StructureSection load='4ZGM' size='340' side='right' caption='Caption for this structure' scene='10/1062575/Semaglutide_peptide/1'> | <StructureSection load='4ZGM' size='340' side='right' caption='Caption for this structure' scene='10/1062575/Semaglutide_peptide/1'> | ||
Revision as of 15:04, 26 October 2024
Semaglutide is an analog of the GLP-1 (glucagon-like peptide-1) hormone. It acts as an agonist to the GLP-1 receptor and is used as drug to manage diabetes. Its use has been growing as a weight-loss medication, and potential benefits across a wide range of diseases is currently studied.
Discovery
Semaglutide was discovered in an effort to increase the lifetime of a once-a-day medication called Liraglutide. It is derived from the GLP-1 hormone, contains two amino acid sequence changes and a covalently attached lipid.
Structure and Receptor Binding
| |||||||||||
